Regulatory guide

Cell-therapy due diligence for patients in Germany

A country-specific starting point for checking product authorisation, trial oversight and cross-border follow-up. This page does not rank providers or recommend medical travel.

What the regulator can confirm

The Paul-Ehrlich-Institut is Germany's competent authority for advanced therapy medicinal products. Its records distinguish centrally authorised ATMPs, authorised clinical trials and the narrowly defined national hospital-exemption route. A provider's location in Germany, a medical-facility licence or a general reference to German standards does not prove that each offered cell or secretome intervention is authorised.

Ask for the product name, classification, manufacturer, indication and the specific PEI, EMA or trial record. If a provider relies on a hospital exemption or another special route, request the authority, scope, named product and current validity. Compare the proposal with established care and obtain independent specialist advice.

Evidence to request before treatment

QuestionDocument or identifierWhy it matters
What exactly is administered?Product name, cell source, processing, dose and routeEvidence and legal status are product- and indication-specific.
What is the legal route?Marketing authorisation, authorised trial number, or named exemption and authorityA clinic licence or registry listing does not by itself authorise a product.
Who manufactures it?Legal manufacturer, site and authorisation scopeGeneral references to GMP are not a substitute for a current, applicable record.
How are harms managed?Consent form, adverse-event plan, insurance and emergency contactExperimental status does not remove the duty to disclose and manage risk.
What happens after travel?Written follow-up plan and named clinicianCross-border care can complicate continuity and reporting.
If the provider will not identify the exact product, legal route and responsible manufacturer in writing, pause before paying or travelling.

Conditions compared

Educational regulatory orientation, reviewed in 2026. Verify current records directly with the authority and seek independent medical advice.

Explore all sections · Data & downloads

Compare cell-therapy evidence, registered studies and published price observations.

StemCellAtlas is a source-first research and cost-planning guide. It separates registry and regulator evidence from heterogeneous commercial observations.

Request written information